CN104491519A - Yin-nourishing and qi-tonifying preparation for aplastic anemia due to dual depletion of qi and blood and preparation method - Google Patents
Yin-nourishing and qi-tonifying preparation for aplastic anemia due to dual depletion of qi and blood and preparation method Download PDFInfo
- Publication number
- CN104491519A CN104491519A CN201410738677.5A CN201410738677A CN104491519A CN 104491519 A CN104491519 A CN 104491519A CN 201410738677 A CN201410738677 A CN 201410738677A CN 104491519 A CN104491519 A CN 104491519A
- Authority
- CN
- China
- Prior art keywords
- preparation
- aplastic anemia
- parts
- petiolus trachycarpi
- fine powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000032467 Aplastic anaemia Diseases 0.000 title claims abstract description 84
- 210000004369 blood Anatomy 0.000 title claims abstract description 63
- 239000008280 blood Substances 0.000 title claims abstract description 63
- 238000002360 preparation method Methods 0.000 title claims abstract description 63
- 230000009977 dual effect Effects 0.000 title abstract 2
- 241000213996 Melilotus Species 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims description 66
- 239000000843 powder Substances 0.000 claims description 45
- 230000007812 deficiency Effects 0.000 claims description 44
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 210000003298 dental enamel Anatomy 0.000 claims description 24
- 229940079593 drug Drugs 0.000 claims description 19
- 239000007788 liquid Substances 0.000 claims description 19
- 239000006187 pill Substances 0.000 claims description 19
- 241000756943 Codonopsis Species 0.000 claims description 18
- 229910000805 Pig iron Inorganic materials 0.000 claims description 14
- 241000244155 Taenia Species 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 7
- 239000012535 impurity Substances 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 6
- 238000009835 boiling Methods 0.000 claims description 5
- 239000012467 final product Substances 0.000 claims description 5
- 230000000694 effects Effects 0.000 abstract description 19
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 4
- 229910052742 iron Inorganic materials 0.000 abstract description 3
- GNKZMNRKLCTJAY-UHFFFAOYSA-N 4'-Methylacetophenone Chemical compound CC(=O)C1=CC=C(C)C=C1 GNKZMNRKLCTJAY-UHFFFAOYSA-N 0.000 abstract description 2
- 235000014290 Artemisia anomala Nutrition 0.000 abstract description 2
- 241000123844 Artemisia anomala Species 0.000 abstract description 2
- 241000607059 Solidago Species 0.000 abstract description 2
- 240000006694 Stellaria media Species 0.000 abstract description 2
- 241000092665 Atractylodes macrocephala Species 0.000 abstract 1
- 241000007126 Codonopsis pilosula Species 0.000 abstract 1
- 235000000839 Melilotus officinalis subsp suaveolens Nutrition 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 231100000331 toxic Toxicity 0.000 abstract 1
- 230000002588 toxic effect Effects 0.000 abstract 1
- 210000000952 spleen Anatomy 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 230000006870 function Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- 231100000614 poison Toxicity 0.000 description 9
- 102000001554 Hemoglobins Human genes 0.000 description 8
- 108010054147 Hemoglobins Proteins 0.000 description 8
- 239000003098 androgen Substances 0.000 description 8
- 208000007502 anemia Diseases 0.000 description 8
- 230000001225 therapeutic effect Effects 0.000 description 8
- 230000017531 blood circulation Effects 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 230000003203 everyday effect Effects 0.000 description 6
- 229930182470 glycoside Natural products 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 6
- 239000003440 toxic substance Substances 0.000 description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 5
- 102000006395 Globulins Human genes 0.000 description 5
- 108010044091 Globulins Proteins 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 241000345998 Calamus manan Species 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 208000033809 Suppuration Diseases 0.000 description 4
- 210000001185 bone marrow Anatomy 0.000 description 4
- 238000010322 bone marrow transplantation Methods 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000006750 hematuria Diseases 0.000 description 4
- 230000033001 locomotion Effects 0.000 description 4
- -1 methyl meticortelone Chemical compound 0.000 description 4
- 235000012950 rattan cane Nutrition 0.000 description 4
- 150000007949 saponins Chemical class 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 201000010000 Agranulocytosis Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 108010069514 Cyclic Peptides Proteins 0.000 description 3
- 102000001189 Cyclic Peptides Human genes 0.000 description 3
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 239000009636 Huang Qi Substances 0.000 description 3
- 206010033557 Palpitations Diseases 0.000 description 3
- 206010033661 Pancytopenia Diseases 0.000 description 3
- 206010047700 Vomiting Diseases 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 108010052008 colla corii asini Proteins 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 3
- 230000003448 neutrophilic effect Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000002574 poison Substances 0.000 description 3
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 230000008673 vomiting Effects 0.000 description 3
- SYTGUXGLBXTALU-UHFFFAOYSA-N 2h-1,4-oxazine-3-carboxylic acid Chemical compound OC(=O)C1=NC=COC1 SYTGUXGLBXTALU-UHFFFAOYSA-N 0.000 description 2
- NESFDGDRYVANBC-UHFFFAOYSA-N 6-(hydroxymethyl)pyridin-3-ol Chemical compound OCC1=CC=C(O)C=N1 NESFDGDRYVANBC-UHFFFAOYSA-N 0.000 description 2
- 241000208838 Asteraceae Species 0.000 description 2
- FBMORZZOJSDNRQ-GLQYFDAESA-N Atractylenolide III Chemical compound C=C([C@@H]1C2)CCC[C@]1(C)C[C@@]1(O)C2=C(C)C(=O)O1 FBMORZZOJSDNRQ-GLQYFDAESA-N 0.000 description 2
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 2
- 235000017491 Bambusa tulda Nutrition 0.000 description 2
- 241000208671 Campanulaceae Species 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 241000209020 Cornus Species 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 241000628997 Flos Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 206010019799 Hepatitis viral Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- FLIACVVOZYBSBS-UHFFFAOYSA-N Methyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC FLIACVVOZYBSBS-UHFFFAOYSA-N 0.000 description 2
- HPEUJPJOZXNMSJ-UHFFFAOYSA-N Methyl stearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC HPEUJPJOZXNMSJ-UHFFFAOYSA-N 0.000 description 2
- 206010068319 Oropharyngeal pain Diseases 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 240000005827 Phyllostachys nigra Species 0.000 description 2
- 244000082204 Phyllostachys viridis Species 0.000 description 2
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000000781 anti-lymphocytic effect Effects 0.000 description 2
- 230000001494 anti-thymocyte effect Effects 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 239000003212 astringent agent Substances 0.000 description 2
- 239000011425 bamboo Substances 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000036461 convulsion Effects 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 230000001882 diuretic effect Effects 0.000 description 2
- HOWGUJZVBDQJKV-UHFFFAOYSA-N docosane Chemical compound CCCCCCCCCCCCCCCCCCCCCC HOWGUJZVBDQJKV-UHFFFAOYSA-N 0.000 description 2
- 208000001780 epistaxis Diseases 0.000 description 2
- XIRNKXNNONJFQO-UHFFFAOYSA-N ethyl hexadecanoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC XIRNKXNNONJFQO-UHFFFAOYSA-N 0.000 description 2
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 2
- HYBBIBNJHNGZAN-UHFFFAOYSA-N furfural Chemical compound O=CC1=CC=CO1 HYBBIBNJHNGZAN-UHFFFAOYSA-N 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000003394 haemopoietic effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 2
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 229960003444 immunosuppressant agent Drugs 0.000 description 2
- 230000001861 immunosuppressant effect Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- JGHZJRVDZXSNKQ-UHFFFAOYSA-N methyl octanoate Chemical compound CCCCCCCC(=O)OC JGHZJRVDZXSNKQ-UHFFFAOYSA-N 0.000 description 2
- XIUXKAZJZFLLDQ-UHFFFAOYSA-N methyl pentadecanoate Chemical compound CCCCCCCCCCCCCCC(=O)OC XIUXKAZJZFLLDQ-UHFFFAOYSA-N 0.000 description 2
- ZAZKJZBWRNNLDS-UHFFFAOYSA-N methyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC ZAZKJZBWRNNLDS-UHFFFAOYSA-N 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- BDJRBEYXGGNYIS-UHFFFAOYSA-N nonanedioic acid Chemical compound OC(=O)CCCCCCCC(O)=O BDJRBEYXGGNYIS-UHFFFAOYSA-N 0.000 description 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- YCOZIPAWZNQLMR-UHFFFAOYSA-N pentadecane Chemical compound CCCCCCCCCCCCCCC YCOZIPAWZNQLMR-UHFFFAOYSA-N 0.000 description 2
- 206010034754 petechiae Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000001047 pyretic effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- KCDXJAYRVLXPFO-UHFFFAOYSA-N syringaldehyde Chemical compound COC1=CC(C=O)=CC(OC)=C1O KCDXJAYRVLXPFO-UHFFFAOYSA-N 0.000 description 2
- YIBXWXOYFGZLRU-UHFFFAOYSA-N syringic aldehyde Natural products CC12CCC(C3(CCC(=O)C(C)(C)C3CC=3)C)C=3C1(C)CCC2C1COC(C)(C)C(O)C(O)C1 YIBXWXOYFGZLRU-UHFFFAOYSA-N 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 201000001862 viral hepatitis Diseases 0.000 description 2
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ADHNUPOJJCKWRT-JLXBFWJWSA-N (2e,4e)-octadeca-2,4-dienoic acid Chemical compound CCCCCCCCCCCCC\C=C\C=C\C(O)=O ADHNUPOJJCKWRT-JLXBFWJWSA-N 0.000 description 1
- XWDAKKDQJHVMKG-LPJPOILFSA-N (8s,9s,10r,13r,14s,17r)-17-[(e,2r,5s)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-1,2,4,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1C=C2CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 XWDAKKDQJHVMKG-LPJPOILFSA-N 0.000 description 1
- SMNDYUVBFMFKNZ-UHFFFAOYSA-N 2-furoic acid Chemical class OC(=O)C1=CC=CO1 SMNDYUVBFMFKNZ-UHFFFAOYSA-N 0.000 description 1
- HRGUSFBJBOKSML-UHFFFAOYSA-N 3',5'-di-O-methyltricetin Chemical compound COC1=C(O)C(OC)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 HRGUSFBJBOKSML-UHFFFAOYSA-N 0.000 description 1
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 1
- ZHESTCBHMHKZNL-UHFFFAOYSA-N 5,7-dihydroxy-6-methoxy-2-(3,4,5-trimethoxyphenyl)chromen-4-one Chemical compound COC1=C(OC)C(OC)=CC(C=2OC3=CC(O)=C(OC)C(O)=C3C(=O)C=2)=C1 ZHESTCBHMHKZNL-UHFFFAOYSA-N 0.000 description 1
- NOEGNKMFWQHSLB-UHFFFAOYSA-N 5-hydroxymethylfurfural Chemical compound OCC1=CC=C(C=O)O1 NOEGNKMFWQHSLB-UHFFFAOYSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 241000208365 Celastraceae Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 description 1
- 244000192528 Chrysanthemum parthenium Species 0.000 description 1
- 235000000604 Chrysanthemum parthenium Nutrition 0.000 description 1
- 241000005787 Cistanche Species 0.000 description 1
- 241001550206 Colla Species 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 description 1
- 108010036949 Cyclosporine Proteins 0.000 description 1
- 206010012218 Delirium Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- FBMORZZOJSDNRQ-UHFFFAOYSA-N Demethoxy,B,HCl-Adriamycin Natural products C1C2C(=C)CCCC2(C)CC2(O)C1=C(C)C(=O)O2 FBMORZZOJSDNRQ-UHFFFAOYSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010018687 Granulocytopenia Diseases 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 102000012428 Hematopoietic Cell Growth Factors Human genes 0.000 description 1
- 108010022580 Hematopoietic Cell Growth Factors Proteins 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 240000000366 Melilotus officinalis Species 0.000 description 1
- 235000017822 Melilotus officinalis Nutrition 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241001007959 Mucuna birdwoodiana Species 0.000 description 1
- UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 1
- 244000183278 Nephelium litchi Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 244000021150 Orbignya martiana Species 0.000 description 1
- 235000014643 Orbignya martiana Nutrition 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000010717 Phyllostachys nigra Nutrition 0.000 description 1
- IDDMFNIRSJVBHE-UHFFFAOYSA-N Piscigenin Natural products COC1=C(O)C(OC)=CC(C=2C(C3=C(O)C=C(O)C=C3OC=2)=O)=C1 IDDMFNIRSJVBHE-UHFFFAOYSA-N 0.000 description 1
- 241001529246 Platymiscium Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- RGDJCYRXKJVXKD-UHFFFAOYSA-N Saponin 3 Natural products COC(=O)C1(C)CCC2(CCC3(C)C(=CCC4C5(C)CCC(OC6OC(CO)C(O)C(O)C6OC7OC(CO)C(O)C(O)C7O)C(C)(C)C5CCC34C)C2C1)C(=O)O RGDJCYRXKJVXKD-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000543826 Sinobambusa Species 0.000 description 1
- 235000000336 Solanum dulcamara Nutrition 0.000 description 1
- 244000197975 Solidago virgaurea Species 0.000 description 1
- 235000000914 Solidago virgaurea Nutrition 0.000 description 1
- 241000800405 Spatholobus suberectus Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- YWJGYBXHXATAQY-UHFFFAOYSA-N Taraxerylacetat Natural products C12CCC3(C)C4CC(C)(C)CCC4(C)CC=C3C1(C)CCC1C2(C)CCC(OC(=O)C)C1(C)C YWJGYBXHXATAQY-UHFFFAOYSA-N 0.000 description 1
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- KGGGRGBDMBZXKF-UHFFFAOYSA-N Virganreagenin G Natural products C1C(O)C(O)C(C)(CO)C2CCC3(C)C4(C)CC(O)C5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C KGGGRGBDMBZXKF-UHFFFAOYSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- YWJGYBXHXATAQY-BOTWUFHUSA-N [(3s,4ar,6ar,6as,8ar,12ar,14ar,14br)-4,4,6a,6a,8a,11,11,14b-octamethyl-1,2,3,4a,5,6,8,9,10,12,12a,13,14,14a-tetradecahydropicen-3-yl] acetate Chemical compound C([C@H]1[C@]2(C)CC[C@H]34)C(C)(C)CC[C@]1(C)CC=C2[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](OC(=O)C)C1(C)C YWJGYBXHXATAQY-BOTWUFHUSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- JZVFJDZBLUFKCA-FXIAWGAOSA-N alpha-Spinasterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)CC[C@H]33)C)C3=CC[C@H]21 JZVFJDZBLUFKCA-FXIAWGAOSA-N 0.000 description 1
- 229930016183 alpha-curcumene Natural products 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940034982 antineoplastic agent Drugs 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- 229940091658 arsenic Drugs 0.000 description 1
- ZZDWUECZDPGSPL-UHFFFAOYSA-N arteanoflavone Natural products COc1cc(cc(O)c1OC)-c1cc(=O)c2c(OC)c(OC)c(O)cc2o1 ZZDWUECZDPGSPL-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 229960002246 beta-d-glucopyranose Drugs 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 231100001018 bone marrow damage Toxicity 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 235000019994 cava Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940097572 chloromycetin Drugs 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001265 ciclosporin Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- DKZBBWMURDFHNE-NSCUHMNNSA-N coniferyl aldehyde Chemical compound COC1=CC(\C=C\C=O)=CC=C1O DKZBBWMURDFHNE-NSCUHMNNSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- CGZZMOTZOONQIA-UHFFFAOYSA-N cycloheptanone Chemical compound O=C1CCCCCC1 CGZZMOTZOONQIA-UHFFFAOYSA-N 0.000 description 1
- 238000004163 cytometry Methods 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 229960000958 deferoxamine Drugs 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CAMHHLOGFDZBBG-UHFFFAOYSA-N epoxidized methyl oleate Natural products CCCCCCCCC1OC1CCCCCCCC(=O)OC CAMHHLOGFDZBBG-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940067592 ethyl palmitate Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 229940056319 ferrosoferric oxide Drugs 0.000 description 1
- 235000008384 feverfew Nutrition 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000001786 gonorrhea Diseases 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 1
- RJGBSYZFOCAGQY-UHFFFAOYSA-N hydroxymethylfurfural Natural products COC1=CC=C(C=O)O1 RJGBSYZFOCAGQY-UHFFFAOYSA-N 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 229940088592 immunologic factor Drugs 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- YAQXGBBDJYBXKL-UHFFFAOYSA-N iron(2+);1,10-phenanthroline;dicyanide Chemical compound [Fe+2].N#[C-].N#[C-].C1=CN=C2C3=NC=CC=C3C=CC2=C1.C1=CN=C2C3=NC=CC=C3C=CC2=C1 YAQXGBBDJYBXKL-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 235000002908 manganese Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 208000007106 menorrhagia Diseases 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 229960000901 mepacrine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N n-hexyl alcohol Natural products CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- YAWXLPDXHPHGPX-UHFFFAOYSA-N nona-2,4-dienoic acid Chemical class CCCCC=CC=CC(O)=O YAWXLPDXHPHGPX-UHFFFAOYSA-N 0.000 description 1
- LQERIDTXQFOHKA-UHFFFAOYSA-N nonadecane Chemical compound CCCCCCCCCCCCCCCCCCC LQERIDTXQFOHKA-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960002895 phenylbutazone Drugs 0.000 description 1
- VYMDGNCVAMGZFE-UHFFFAOYSA-N phenylbutazonum Chemical compound O=C1C(CCCC)C(=O)N(C=2C=CC=CC=2)N1C1=CC=CC=C1 VYMDGNCVAMGZFE-UHFFFAOYSA-N 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- YQUVCSBJEUQKSH-UHFFFAOYSA-N protochatechuic acid Natural products OC(=O)C1=CC=C(O)C(O)=C1 YQUVCSBJEUQKSH-UHFFFAOYSA-N 0.000 description 1
- GPKJTRJOBQGKQK-UHFFFAOYSA-N quinacrine Chemical compound C1=C(OC)C=C2C(NC(C)CCCN(CC)CC)=C(C=CC(Cl)=C3)C3=NC2=C1 GPKJTRJOBQGKQK-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 235000004400 serine Nutrition 0.000 description 1
- RPLOPBHEZLFENN-HTMVYDOJSA-M sodium;4-[(2r,3r)-2-[(2,2-dichloroacetyl)amino]-3-hydroxy-3-(4-nitrophenyl)propoxy]-4-oxobutanoate Chemical compound [Na+].[O-]C(=O)CCC(=O)OC[C@@H](NC(=O)C(Cl)Cl)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 RPLOPBHEZLFENN-HTMVYDOJSA-M 0.000 description 1
- 229930182680 solidagosaponin Natural products 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- PKXVFQDVNGNKNY-IOIRRTEJSA-N stigmasterone Natural products CC[C@H](C=C[C@@H](C)[C@H]1CC[C@H]2[C@@H]3CC=C4CC(=O)CC[C@]4(C)[C@H]3C(=O)C[C@]12C)C(C)C PKXVFQDVNGNKNY-IOIRRTEJSA-N 0.000 description 1
- 230000004206 stomach function Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- QJVXKWHHAMZTBY-GCPOEHJPSA-N syringin Chemical compound COC1=CC(\C=C\CO)=CC(OC)=C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 QJVXKWHHAMZTBY-GCPOEHJPSA-N 0.000 description 1
- QJVXKWHHAMZTBY-KSXIZUIISA-N syringin Natural products COc1cc(C=CCO)cc(OC)c1O[C@H]2O[C@@H](CO)[C@H](O)[C@@H](O)[C@@H]2O QJVXKWHHAMZTBY-KSXIZUIISA-N 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000008492 tangshen Substances 0.000 description 1
- GGGUGZHBAOMSFJ-GADYQYKKSA-N taraxerol Chemical compound CC([C@@H]1CC2)(C)[C@@H](O)CC[C@]1(C)[C@@H]1[C@]2(C)C2=CC[C@@]3(C)CCC(C)(C)C[C@H]3[C@]2(C)CC1 GGGUGZHBAOMSFJ-GADYQYKKSA-N 0.000 description 1
- HYTFUKZLSYXRDX-UHFFFAOYSA-N taraxerol Natural products CC1CCCC2C3(C)CCC4(C)C5CC(C)(C)CCC5(C)C=CC4(C)C3C(O)CC12C HYTFUKZLSYXRDX-UHFFFAOYSA-N 0.000 description 1
- ZNMILUODKSYHAH-UHFFFAOYSA-N taraxeryl acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C2CCC4C5CC(C)(C)CCC5(C)CC=C34)C1(C)C ZNMILUODKSYHAH-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 150000003515 testosterones Chemical class 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 235000008521 threonine Nutrition 0.000 description 1
- 239000003634 thrombocyte concentrate Substances 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- DKZBBWMURDFHNE-UHFFFAOYSA-N trans-coniferylaldehyde Natural products COC1=CC(C=CC=O)=CC=C1O DKZBBWMURDFHNE-UHFFFAOYSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- BMCJATLPEJCACU-UHFFFAOYSA-N tricin Natural products COc1cc(OC)c(O)c(c1)C2=CC(=O)c3c(O)cc(O)cc3O2 BMCJATLPEJCACU-UHFFFAOYSA-N 0.000 description 1
- IRYJRGCIQBGHIV-UHFFFAOYSA-N trimethadione Chemical compound CN1C(=O)OC(C)(C)C1=O IRYJRGCIQBGHIV-UHFFFAOYSA-N 0.000 description 1
- 229960004453 trimethadione Drugs 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- WKOLLVMJNQIZCI-UHFFFAOYSA-N vanillic acid Chemical compound COC1=CC(C(O)=O)=CC=C1O WKOLLVMJNQIZCI-UHFFFAOYSA-N 0.000 description 1
- TUUBOHWZSQXCSW-UHFFFAOYSA-N vanillic acid Natural products COC1=CC(O)=CC(C(O)=O)=C1 TUUBOHWZSQXCSW-UHFFFAOYSA-N 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/486—Millettia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/889—Arecaceae, Palmae or Palmaceae (Palm family), e.g. date or coconut palm or palmetto
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a yin-nourishing and qi-tonifying preparation for aplastic anemia due to dual depletion of qi and blood and a preparation method of the preparation. The preparation is prepared from the following main raw materials in parts by weight: 9-18 parts of codonopsis pilosula, 6-12 parts of sweet clover, 2-5 parts of artemisia anomala, 10-15 parts of caulis spatholobi, 12-22 parts of caulis bambusae in taeniam, 10-20 parts of atractylodes macrocephala koidz, 6-12 parts of solidago, 6-9 parts of stellaria yunnanensis, 3-6 parts of raw iron scale, 6-12 parts of platycodon grandiflorum and 3-6 parts of crinis trachycarpi. The yin-nourishing and qi-tonifying preparation has the advantages of high effective rate, significant curative effect, good safety, low treatment cost, and no toxic or side effect, and is capable of treating both symptoms and root causes.
Description
Technical field
The present invention relates to traditional Chinese medicine field, particularly relate to a kind of both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation and preparation method thereof.
Background technology
Aplastic anemia (abbreviation aplastic anemia) is one group and causes bone marrow stem cell and hematopoieticmicroenviron-ment to damage by chemistry, biology, physical factor and unknown cause, so that red pulp is replaced by fatty marrow, the disease of pancytopenia.Aplastic anemia is generally divided into acute aplastic anemia and chronic aplastic anemia, clinical main manifestations for dizzy, have palpitation, breathe hard, weak, yellowish complexion, lip, fingernail are pale, dermatorrhagia point, ecchymosis, gums oozing of blood, menorrhagia, low grade fever, can occur high heat during concurrent infection.The morbidity of aplastic anemia may be relevant with following factors: (1) medicine.Medicine is modal pathogenic factors.Drug aplastic anemia has two types: 1. relevant with dosage, is dealed with medicine went, and reaching doses will cause bone marrow depression, is generally reversible, as various antineoplastic agent.2. little with dose relationship, only there is hematopoietic disorders in few patients, the anaphylaxis of polyphyly medicine, often causes persistence aplastic anemia.This kind of medicament categories is various, common are chlorine (conjunction) mycin, organo-arsenic, atabrine, trimethadione, Phenylbutazone etc.Drug aplastic anemia is the most common to be caused by chloromycetin.(2) chemical toxicant.Benzene and derivative thereof and aplastic anemia relation are by many experimentatioies are affirmed.Since reform and opening-up, township enterprise rises, and owing to not noting labor protection, caused by benzene aplastic anemia sickness rate rises to some extent.(3) ionizing radiation.Exceed lonizing radiation allowance irradiation (as radioactive source accident) for a long time and can cause aplastic anemia.(4) viral infection.The relation of viral hepatitis and aplastic anemia is comparatively affirmed, is called Viral Hepatitis aplastic anemia.(5) immune factor.Aplastic anemia secondary can do the immunologic derangement diseases such as thymoma systemic lupus erythematosus (sle) and rheumatoid arthritis.From traditional Chinese medical science angle, aplastic anemia be because body deficiency of kidney-essence, experience external evil poison, healthy energy is deficient, can not resist heresy, and evil poison caves in, induced renal damage, and consumption is impairment of the kidney essence.Deficiency of kidney-essence, can not supplement nutrition bone marrow, bone marrow is hollow, can not biochemical blood, accumulate in evil poison, not only can consume essence of being impairment of the kidney, blood vessels can also be blocked and run, cause congestion, congestion is not dispelled, fresh blood not life, forms vicious cycle, so the basic pathology of aplastic anemia is to accumulate in deficiency of kidney-essence, pyretic toxicity, congestion resistance network.
Common treatment of aplastic anemia comprises: (one) supporting treatment.All materials of bone marrow damage that likely causes all should manage to remove, and forbidding all has inhibiting medicine to bone marrow.Actively carry out Personal hygiene and nursery work.To the suitable Protective isolation of agranulocytosis person, active prevention infects.Blood transfusion GPRS indication, goes to bone marrow transplantation person, and before transplanting, blood transfusion can directly affect its success rate, especially can not the blood of defeated family member.General is appropriate to input Red Blood Cells Concentrate.Severe haemorrhage person should input Platelet Concentrate, and the platelet transfusion adopting per unit area yield or HLA to be harmonious can improve curative effect.Transfusion person should apply the treatment of deferoxamine row ferrum.(2) androgen is treatment chronic aplastic anemia choice drug.Conventional androgen has four classes: 1. 17 alpha-alkyl androgens; 2. Testosterone esters; 3. non-17 alpha-alkyl androgens; 4. intermediate active metabolite etc.(3) bone marrow transplantation is the best approach that treatment stem cell defect causes aplastic anemia, and can reach the object of radical cure.Once make a definite diagnosis Severe or pole Severe aplastic anemia, age < 20 years old, HLA distribution type is had to conform to donor, first-selected allogeneic bone marrow transplantation is answered in hospital with good conditionsi, after transplanting, Long-term disease-free survival rate can reach 60% ~ 80%, but transplanting need be carried out, as early as possible because of the normal red cells transfusion of first visit person and platelet, easily like this make receptor to blood donor minor histocompatibility antigen sensitization, cause transplant rejection incidence rate to raise.(4) immunosuppressant is applicable to the age and is greater than 40 years old or without the suitable Severe aplastic anemia for marrow person.The most frequently used is anti-thymus globulin (ATG) and antilymphocyte globulin (ALG).(5) Chinese medicine is controlled should the kidney invigorating be this, benefiting QI for activating blood circulation of holding concurrently.Conventional Chinese medicine is Colla cornus cervi, Rhizoma Curculiginis, Herba Epimedii, the Radix Astragali, raw Radix Rehmanniae Preparata, the Radix Polygoni Multiflori, Radix Angelicae Sinensis, Herba Cistanches, Ba Ji, Fructus Psoraleae, Semen Cuscutae, Fructus Lycii, Colla Corii Asini etc.State's internal therapy chronic aplastic anemia is commonly used androgen and is merged the treatment of traditional Chinese medical science Kidney-Nourishing.(6) hematopoietic cytokine and therapeutic alliance aplastic anemia are the anemias that hematopoietic stem cell disorder causes, endogenous plasma EPO level is all at more than 500u/L, effectively, general dosage to obtain any effect to adopt recombinant human epo to treat the required heavy dose of just possibility of aplastic anemia.Recombinant Human Colony Stimulating Factors comprises G-CSF, GM-CSF or IL-3 and treats aplastic anemia to raising neutrophilic granulocyte, and reducing infection may have certain effect, but to improving anemia and thrombocytopenia poor effect, unless heavy dose of application.But hematopoietic cytokine is expensive, be therefore only limitted to adjuvant drug during Severe aplastic anemia immunosuppressant treatment at present, as application ALG/ATG treats Severe aplastic anemia, often the accompanying infection because there is serious agranulocytosis, causes Deaths.If now merging application rHG-CSF can improve early stage grain and lack, reduce case fatality rate.Therapeutic alliance can improve Severe aplastic anemia therapeutic effect, comprise ALG/ATG and CSA therapeutic alliance, CSA and androgen therapeutic alliance etc., European blood and bone marrow transplantation group adopt ALG, CSA, methyl meticortelone and rhG-CSF therapeutic alliance, bring up to 82% to Severe aplastic anemia effective percentage.
Application publication number CN 102727707 A(application number 201110093191.7) Chinese patent literature disclose a kind of pharmaceutical composition for the treatment of leukemia and aplastic anemia, said composition is made up of Radix Rehmanniae Preparata, the Radix Polygoni Multiflori, the Radix Rehmanniae, Cortex Moutan, Radix Angelicae Sinensis, Fructus Forsythiae, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Cortex Cinnamomi, Flos Lonicerae, Carapax et Plastrum Testudinis, the Radix Paeoniae Alba, Colla Corii Asini, Radix Glycyrrhizae, Radix Codonopsis, Rhizoma Dioscoreae, Fructus Lycii, Fructus Schisandrae Chinensis, Cornu Bubali, Lignum Sappan, Rhizoma Chuanxiong, Radix Platycodonis and Radix Cyathulae.Application publication number CN 103784583 A(application number 201210423876.8) Chinese patent literature disclose a kind of medicine for the treatment of anemia, the crude drug making effective ingredient forms by following weight: Herba Agrimoniae 25-35 gram, Caulis Spatholobi 15-25 gram, Radix Astragali 15-25 gram, Fructus Ligustri Lucidi 10-20 gram, Fructus Rubi 10-20 gram, Radix Angelicae Sinensis 10-18 gram, Radix Rehmanniae Preparata 10-18 gram, Herba Epimedii 10-18 gram, Fructus Psoraleae 10-18 gram, Radix Morindae Officinalis 5-15 gram, Colla Corii Asini 5-15 gram.Application publication number CN 104147341 A(application number 201410439407.4) Chinese patent literature disclose a kind of Chinese medicine for the treatment of anemia, pressed certain weight ratio synthesized by Semen Sesami Nigrum, Caulis Spatholobi, Fructus Jujubae, dried Fructus Litchi, Fructus Lycii, Bulbus Lilii, Endothelium Corneum Gigeriae Galli, Radix Gossypii, Flos Carthami, Rhizoma Cannae Indicae (Radix Cannae Indicae), Radix Glycyrrhizae.
The Drug therapy of current aplastic anemia there is no specially good effect, doctor trained in Western medicine is androgen, immune formulation and the Supporting Therapys such as blood transfusion, infection of suiting the medicine to the illness mainly, after drug withdrawal, symptom there will be again, than being easier to repeatedly, it is the method for curing the symptoms, not the disease, and side effect is large, effective percentage is relatively low, and medical expense is higher.
Summary of the invention
For the deficiencies in the prior art, the object of this invention is to provide a kind of both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation and preparation method thereof.Effective percentage of the present invention is high, evident in efficacy, treating both the principal and secondary aspects of a disease, safety, medical expense are low, have no side effect.
Technical scheme of the present invention is:
Both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation, take off the primary raw material medicine stating weight proportion to be prepared from: Radix Codonopsis 9-18, melilotus 6-12, Herba Artemisiae Anomalae 2-5, Caulis Spatholobi 10-15, Caulis Bambusae In Taenia 12-22, Rhizoma Atractylodis Macrocephalae 10-20, Herba Solidaginis 6-12, Radix Stellariae Yunnanensis 6-9, the pig iron falls 3-6, Radix Platycodonis 6-12, charred Petiolus Trachycarpi 3-6.
Both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation, preferred scheme is, takes off the primary raw material medicine stating weight proportion and is prepared from: Radix Codonopsis 12-16, melilotus 8-10, Herba Artemisiae Anomalae 3-4.3, Caulis Spatholobi 12-14, Caulis Bambusae In Taenia 15-18, Rhizoma Atractylodis Macrocephalae 13-17, Herba Solidaginis 7-9, Radix Stellariae Yunnanensis 7-8.5, the pig iron falls 4-5, Radix Platycodonis 8-11, charred Petiolus Trachycarpi 4-5.
Both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation, the scheme be more preferably is, takes off the primary raw material medicine stating weight proportion and is prepared from: Radix Codonopsis 14, melilotus 8.5, Herba Artemisiae Anomalae 3.8, Caulis Spatholobi 13, Caulis Bambusae In Taenia 16, the Rhizoma Atractylodis Macrocephalae 15, Herba Solidaginis 8, Radix Stellariae Yunnanensis 7.5, the pig iron falls 4.3, Radix Platycodonis 9, charred Petiolus Trachycarpi 4.5.
Present invention also offers the preparation method aforementioned both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation being made pharmaceutically acceptable decoction, powder and pill.
The preparation method of described decoction is:
(1) enamel tray is put in electrothermostat and is reached 140-200 DEG C after (preferred, after enamel tray is put in electrothermostat and is reached 150-190 DEG C; Be more preferably, enamel tray put in electrothermostat and reaches after 180 DEG C), put into Petiolus Trachycarpi rapidly, baking 5-15 min(is preferred, baking 8-12 min; Be more preferably, toast 10 min), taking-up cools, and is ground into fine powder, crosses 150-190 mesh sieve and (preferably, crosses 160-180 mesh sieve; Be more preferably, cross 170 mesh sieves), obtain charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is placed in marmite, adds water, amount of water is that doubly (preferred, amount of water is 3.5-4.5 times of the medicine gross weight added to the 3-5 of the medicine gross weight added; Be more preferably, amount of water is 4 times of the medicine gross weight added), first boil to boiling with big fire, to decoct with little fire afterwards, when to decoct to medicinal liquid be the 1/4-1/2 of amount of water (preferred, when to decoct to medicinal liquid be the 2/7-2/5 of amount of water; Be more preferably, when to decoct to medicinal liquid be 1/3 of amount of water), leach medicinal liquid;
(3) step (1) gained charred Petiolus Trachycarpi fine powder is joined in step (2) gained medicinal liquid, to obtain final product.
The preparation method of described powder is:
(1) enamel tray is put in electrothermostat and is reached 130-190 DEG C after (preferred, after enamel tray is put in electrothermostat and is reached 150-180 DEG C; Be more preferably, enamel tray put in electrothermostat and reaches after 165 DEG C), put into Petiolus Trachycarpi rapidly, baking 10-20 min(is preferred, baking 12-17min; Be more preferably, baking 15min), taking-up cools, and is ground into fine powder, crosses 130-170 mesh sieve (preferably, 140-160 mesh sieve; Be more preferably, cross 150 mesh sieves), obtain charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is removed impurity, pulverize respectively and grind to form fine powder, cross 130-170 mesh sieve and (preferably, cross 140-160 mesh sieve; Be more preferably, cross 150 mesh sieves);
(3) step (1) and step (2) gained fine powder are fully mixed, sterile packaged, often wrap 4 grams.
The preparation method of described pill is:
(1) enamel tray is put in electrothermostat and is reached 140-180 DEG C after (preferred, after enamel tray is put in electrothermostat and is reached 150-170 DEG C; Be more preferably, enamel tray put in electrothermostat and reaches after 160 DEG C), put into Petiolus Trachycarpi rapidly, baking 8-25 min(is preferred, baking 14-20min; Be more preferably, baking 17min), taking-up cools, and is ground into fine powder, crosses 140-180 mesh sieve and (preferably, crosses 150-170 mesh sieve; Be more preferably, cross 160 mesh sieves), obtain charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is removed impurity, pulverize respectively and grind to form fine powder, cross 140-180 mesh sieve and (preferably, cross 150-170 mesh sieve; Be more preferably, cross 160 mesh sieves);
(3) step (1) and step (2) gained fine powder are fully mixed, add water, make little pill, the particle diameter of the little pill made is that 2-6mm(is preferred, and the particle diameter of the little pill made is 3-5mm; Be more preferably, the particle diameter of the little pill made is 4mm), dry and can obtain pill finished product of the present invention.
The pharmacology of the present invention's main raw material of Chinese medicine used is as follows:
Radix Codonopsis: base is former: be the dry root of Campanulaceae Radix Codonopsis, element flower Radix Codonopsis or radix codonpsis tangshen etc.Radix Codonopsis has containing sterols: hitodesterol, stigmasterol, hitodesterol-β-D-Glucose glycoside, stigmasterol-β-D-Glucose glycoside, α-Herba Spinaciae sterone, stigmasterone etc.Sugar and glycoside have: inulin, fructose, four kinds of heteropolysaccharide containing fructose.Syringin, β-D-Glucopyranose. hexanol glycoside, α-D-fructofuranose ethanol glycoside.Alkaloid and nitrogen containing component have: choline, normal-butyl allophanate, codopiloic acid, 5-hydroxy-2-hydroxymethylpyridine, nicotine.Volatile ingredient has: caproic acid, enanthic acid, sad, n-nonanoic acid, dodecoic acid, Azelaic Acid, tetradecylic acid, pentadecanoic acid, hexadecylic acid, stearic acid, octadecadienoic acid, 2,4-nonadienoic acids, Pentadecane, α-curcumene, n-heptadecane, n-octadecane, AI3-36122, positive 21 alkane, positive docosane, methyl myristate, pentadecanoic acid methyl ester, methyl palmitate, methyl stearate, octadecadienoic methyl, pinene, ethyl palmitate, methyl caprylate.Still containing triterpenes and other compositions: alnulin, Taraxeryl acetate, suberone; Atractyloide II, III; Syringic aldehyde, vanillic acid, 2-furan carboxylic esters, codonolactone, 5 hydroxymethyl furfural, 5-methoxyl group furfural.In addition, the also 17 seed amino acid property of medicine such as 14 kinds of inorganic elementss such as iron content, zinc, copper, manganese and aspartic acid, threonine, serine, glutamic acid: sweet, flat.Return spleen, lung meridian.Function cures mainly: invigorating the spleen and replenishing QI, spleen invigorating lung benefiting.For deficiency of the spleen and lung, cardiopalmus of breathing hard, anorexia and loose stool, dyspnea due to deficiency is coughed, and interior-heat is quenched one's thirst.
Melilotus: base is former: be the herb of pulse family melilot serration melilotus.Composition: herb, containing volatile oil, includes coumarin.The property of medicine: " Inner Mongol Chinese herbal medicine ": " acrid in the mouth, property is put down." function cures mainly: " Inner Mongol Chinese herbal medicine ": " with middle stomach invigorating, clearing away heat and eliminating dampness, diuresis.Cure mainly heat-damp in summer uncomfortable in chest, greasy taste in the mouth, halitosis, dysentery with red and white feces, gonorrhea, furuncle.
Herba Artemisiae Anomalae: have another name called Herba Artemisiae Anomalae grass, Herba Senecionis Scandentis is the wounded in the battle herb of Compositae sagebruss artemisia anomalas.The property of medicine: stem is cylindrical, surperficial brown color or brown-green, matter is hard and crisp, frangibility, the integrated spike panicle of head inflorescence, withered yellow, gas fragrance, bitter in the mouth, pungent, warm in nature.GUIXIN, liver, spleen channel.Composition: mainly containing arteanoflavone, tricin, apigenin, Palmic acid etc.Find according to modern pharmacological research, this medical instrument has effect of anti-hypoxia, blood circulation promoting and blood stasis dispelling, removing food stagnancy, hemostasia and detumescence, for amenorrhea due to stagnation of blood, and abdominal pain due to retention of food, hematuria, the diseases such as scald.
Caulis Spatholobi: base is former: be the rattan of leguminous plant spatholobus suberectus, Mucuna birdwoodiana, fragrant flower Moghania fluminalis(C. B. Clarke) Li rattan or bright leaf Moghania fluminalis(C. B. Clarke) Li rattan etc.Chemical analysis: fragrant flower Moghania fluminalis(C. B. Clarke) Li rattan is containing milletol.The property of medicine: bitter sweet, temperature." book on Chinese herbal medicine is new again ": " enter the heart, spleen two warp." function cures mainly: to invigorate blood circulation, relaxing muscles and tendons.Control soreness of waist and knee joint, paralysis and numbness, menoxenia.
Caulis Bambusae In Taenia: base is former: the intermediate layer that the stem stalk for grass family Phyllostachys plant phyllostachys nigra (lodd.ex lindl.) munro var.henonis (miff.) spapf et rendle, the blue or green pole bamboo of Thorny Sinobambusa plant, Sinocalamus plant major part allusion quotation bamboo etc. goes crust to scrape.Composition: the Caulis Bambusae In Taenia of phyllostachys nigra (lodd.ex lindl.) munro var.henonis (miff.) spapf et rendle is containing phenolic constituent: 2,5-dimethoxy-1,4-benzoquinone, hydroxy benzaldehyde, syringic aldehyde, coniferyl aldehyde.Another containing p-phthalic acid 2 '-hydroxyethyl methyl ester.The property of medicine: sweet, is slightly cold.Return spleen, stomach, gallbladder meridian.Function cures mainly: removing heat-phlegm, relieves restlessness and prevents vomiting, antiabortive removing heat from blood.Cure mainly cough due to lung-heat, dysphoria with smothery sensation is palpitated with fear, and gastric heat is vomitted oh, pregnancy reactions, frequent fetal movement, spits blood, epistaxis, hematuria, metrorrhagia.
The Rhizoma Atractylodis Macrocephalae: base is former: be the dry rhizome of the feverfew Rhizoma Atractylodis Macrocephalae.The property of medicine: bitter, sweet, temperature.Return spleen, stomach warp.Function cures mainly: invigorating the spleen and benefiting QI, dampness diuretic, and hidroschesis is antiabortive.For insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration, frequent fetal movement.Rhizoma Atractylodis Macrocephalae spleen invigorating, stomach function regulating, antiabortive.For insufficiency of the spleen lack of appetite, loose stool of having loose bowels, frequent fetal movement.
Herba Solidaginis: base is former: be herb or the root of Compositae Herba Solidaginis platymiscium Herba Solidaginis.Composition: aerial parts is containing saponin component: Herba Solidaginis glycosides, activities of Solidago virgaurea L saponin 3 that is 3, Solidago saponin, solidago canadesis saponin, huge Herba Solidaginis saponin, the triterpene glycosides etc. of Polygalacic acid.The property of medicine: pungent, bitter, cool.Function cures mainly: wind and heat dispersing, removing toxic substances and promoting subsidence of swelling.Cure mainly anemopyretic cold, laryngopharynx swelling and pain, cough due to lung-heat, jaundice, pyretic stranguria, carbuncle furuncle, venom, traumatic injury.
Radix Stellariae Yunnanensis: base is former: be the root of Caryophyllaceae Stellaria plant Yunnan Herba stellariae mediae.Composition: containing peptide class: Herba stellariae mediae cyclic peptide A, B, C, D, E, F, G, false Herba stellariae mediae cyclic peptide A-H, Yunnan Herba stellariae mediae cyclic peptide A, B, D, C, E, F.The property of medicine: sweet, flat.Function cures mainly: strengthening spleen and nourishing blood, invigorating the liver and kidney, detumescence.Cure mainly anemia, dizzy nervous, tinnitus hectic fever, the soreness of waist, seminal emission, menoxenia, leukorrhagia, fracture, mastitis.The pig iron falls: base is former: for being hammered into shape the iron filings fallen when the pig iron is calcined to red red, outer oxide.Composition: main containing ferroso-ferric oxide, or name magnetic oxide.The property of medicine: pungent, cool.GUIXIN, Liver Channel.Function cures mainly: checking hyperfunction of the liver for relieving convulsion, and removing toxic substances sore, enriches blood.Cure mainly demented, febrile delirium, palpitation and being susceptible to fright, rheumatic arthralgia, skin infection swells and ache, anemia.Compatibility and incompatibility of drugs: deficiency of the liver and the middle deficiency of vital energy person of trembling with fear prohibit clothes.
Radix Platycodonis: base is former: be the root of Campanulaceae Radix Platycodonis.The property of medicine: bitter, pungent, flat.Return lung meridian.Function cures mainly: have lung qi dispersing, and sore-throat relieving eliminates the phlegm, effect of evacuation of pus.For cough with copious phlegm, uncomfortable in chest smooth, pharyngalgia, hoarseness, lung abscess vomiting pus, skin infection difficulty in discharging of pus.
Petiolus Trachycarpi: this product is the dry petiole of babassu Petiolus Trachycarpi.The property of medicine: bitter, puckery, flat.Return lung, liver, large intestine channel.Function cures mainly: hemostasis with astringents.For spitting blood, epistaxis, hematuria, has blood in stool, metrostaxis.Charred Petiolus Trachycarpi: after enamel tray is put in electrothermostat and reached temperature, put into Petiolus Trachycarpi rapidly, baking, taking-up cools.
Both Qi and blood deficiency provided by the invention " aplastic anemia " enriching yin boost qi preparation compatibility is scientific and reasonable, and preparation method is simple.In addition, excellent results of the present invention also shows:
1, there is enriching yin boost qi, spleen invigorating lung benefiting, blood circulation promoting and blood stasis dispelling, hemostasia and detumescence, heat-clearing and toxic substances removing, invigorating the liver and kidney, blood-supplementing blood-nourishing
Etc. effect;
2, evident in efficacy, treating both the principal and secondary aspects of a disease;
, have no side effect 3, safely;
4, medical expense is low.
Detailed description of the invention
Describe technical scheme of the present invention in detail below in conjunction with embodiment and experimental example, but protection domain is not limited thereto.
embodiment 1both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation, the primary raw material medicine getting following weight parts is prepared from (every part is 20g): Radix Codonopsis 9 parts, melilotus 6 parts, Herba Artemisiae Anomalae 2 parts, Caulis Spatholobi 10 parts, Caulis Bambusae In Taenia 12 parts, the Rhizoma Atractylodis Macrocephalae 10 parts, Herba Solidaginis 6 parts, Radix Stellariae Yunnanensis 6 parts, the pig iron falls 3 parts, Radix Platycodonis 6 parts, charred Petiolus Trachycarpi 3 parts.
The preparation method of above-mentioned both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation decoction is:
(1) enamel tray is put in electrothermostat reach after 140 DEG C, put into Petiolus Trachycarpi rapidly, baking 5min, taking-up cools, and is ground into fine powder, crosses 150 mesh sieves, obtains charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is placed in marmite, adds water, amount of water is 3 times of the medicine gross weight added, and first boils to boiling with big fire, decocts with little fire afterwards, when to decoct to medicinal liquid be 1/4 of amount of water, leaches medicinal liquid;
(3) step (1) gained charred Petiolus Trachycarpi fine powder is joined in step (2) gained medicinal liquid, to obtain final product.
Decoction instructions of taking of the present invention: oral, every day twice, each 300mL(is warm).
embodiment 2both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation, the primary raw material medicine getting following weight parts is prepared from (every part is 20g): Radix Codonopsis 18 parts, melilotus 12 parts, Herba Artemisiae Anomalae 5 parts, Caulis Spatholobi 15 parts, Caulis Bambusae In Taenia 22 parts, the Rhizoma Atractylodis Macrocephalae 20 parts, Herba Solidaginis 12 parts, Radix Stellariae Yunnanensis 9 parts, the pig iron falls 6 parts, Radix Platycodonis 12 parts, charred Petiolus Trachycarpi 6 parts.
The preparation method of above-mentioned both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation decoction is:
(1) enamel tray is put in electrothermostat reach after 200 DEG C, put into Petiolus Trachycarpi rapidly, toast 15 min, taking-up cools, and is ground into fine powder, crosses 190 mesh sieves, obtains charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is placed in marmite, adds water, amount of water is 5 times of the medicine gross weight added, and first boils to boiling with big fire, decocts with little fire afterwards, when to decoct to medicinal liquid be 1/2 of amount of water, leaches medicinal liquid;
(3) step (1) gained charred Petiolus Trachycarpi fine powder is joined in step (2) gained medicinal liquid, to obtain final product.
model case one:king XX, female, 18 years old.She or the student of senior middle school one grade of 18 years old, should she of happy health, is but diagnosed as aplastic anemia.One time, dark clouds shroud she and her family.Through the treatment of 11 months, disease was not fully recovered, and medical cost of hospitalization has but spent more than 30 ten thousand yuan, allow her back heavy debt, unable continuation be in hospital she, can only rely on blood transfusion and platelet to maintain stable disease.She one be stymied by, it is pretty good that well-wisher introduces effect of the present invention, says and allow her have a try.She starts to receive treatment of the present invention like this.Take both Qi and blood deficiency of the present invention " aplastic anemia " enriching yin boost qi preparation decoction, oral, every day twice, each 300mL(is warm).Take after two months, her state of an illness just stabilizes, the mental status, also have strength with it, lip also obviously has color.This makes the mood of she one family quite a lot of slightly.
After taking 3 months, her hemoglobin and leukocyte rise obviously, to have a blood test routine: WBC 3.8 × 10 to hospital
9/ L, Hb 85g/L, PLT 30 × 10
9/ L, her state of an illness gets better every day.After taking four months, her routine blood test reaches WBC 4.6 × 10
9/ L, Hb 118g/L, PLT 82 × 10
9/ L.This allows she and her household feel incomparable happy and gratified.The adolescent girl of 18 years old, the struggle of process and the serious illness, has gone on the road of health finally!
embodiment 3both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation, the primary raw material medicine getting following weight parts is prepared from (every part is 20g): Radix Codonopsis 12 parts, melilotus 8 parts, Herba Artemisiae Anomalae 3 parts, Caulis Spatholobi 12 parts, Caulis Bambusae In Taenia 15 parts, the Rhizoma Atractylodis Macrocephalae 13 parts, Herba Solidaginis 7 parts, Radix Stellariae Yunnanensis 7 parts, the pig iron falls 4 parts, Radix Platycodonis 8 parts, charred Petiolus Trachycarpi 4 parts.
The preparation method of above-mentioned both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation powder is:
(1) enamel tray is put in electrothermostat reach after 165 DEG C, put into Petiolus Trachycarpi rapidly, toast 15 min, taking-up cools, and is ground into fine powder, crosses 150 mesh sieves, obtains charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is removed impurity, pulverize respectively and grind to form fine powder, cross 150 mesh sieves;
(3) step (1) and step (2) gained fine powder are fully mixed, sterile packaged, often wrap 4 grams.
model case two: yellow XX, female, 50 years old.Main suit: suddenly felt uncomfortable before 3 years, walk dizzy, breathe hard, the heart throbs and not to stop.Often with having a fever, feeling sick, and menstrual blood volume is very large, cannot normally go to work.Under the accompanying of layman, go to a doctor to local hospital.After three days, bone wears report finally out, is diagnosed as the poisoning aplastic anemia caused of unknown cause, routine blood test display pancytopenia, at that time hemoglobin only 3.6 grams.Under the bimestrial western medicine of hospital, not only the state of an illness does not take a turn for the better, and is degrading on the contrary, has unexpectedly occurred hematuria, had blood in stool.The even section of having time stomatitis, even speak, having a meal also has become problem, have also appeared the ecchymosis of many places, petechia with it.Introduce the present invention through friend and treat aplastic anemia effect very well, have a sense of hope in arms, she determines to make a try.Take both Qi and blood deficiency of the present invention " aplastic anemia " enriching yin boost qi preparation powder, every day twice, each 4 grams, warm water delivery service.After taking 30 days, she reverts to the same with normal person substantially.Continue to take two months, her gingiva, nasal cavity are spontaneous hemorrhagely to be stopped substantially, and subcutaneous fleckiness is also absorbed completely.Also outdoor can be arrived to do simple motion.After one week, make individual bone in locality again and worn.Bone wears report display " red system hypertrophy, disease amelioration ".Continue to take 1 month, her state of an illness is continual and steady.
embodiment 4both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation, the primary raw material medicine getting following weight parts is prepared from (every part is 20g): Radix Codonopsis 16 parts, melilotus 10 parts, Herba Artemisiae Anomalae 4.3 parts, Caulis Spatholobi 14 parts, Caulis Bambusae In Taenia 18 parts, the Rhizoma Atractylodis Macrocephalae 17 parts, Herba Solidaginis 9 parts, Radix Stellariae Yunnanensis 8.5 parts, the pig iron falls 5 parts, Radix Platycodonis 11 parts, charred Petiolus Trachycarpi 5 parts.
The preparation method of above-mentioned both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation pill is:
(1) enamel tray is put in electrothermostat reach after 160 DEG C, put into Petiolus Trachycarpi rapidly, baking 17min, taking-up cools, and is ground into fine powder, crosses 160 mesh sieves, obtains charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is removed impurity, pulverize respectively and grind to form fine powder, cross 160 mesh sieves;
(3) step (1) and step (2) gained fine powder are fully mixed, add water, make little pill, the particle diameter of the little pill made is 4mm, dries and can obtain pill finished product of the present invention.
model case three:lee XX, man, 19 years old.One day, he found that petechia appears in the many places such as the arm skin of oneself, removes hospital admission, checks in: leukocyte 0.92 × 10 after ten days
9/ L, hemoglobin 92g/L, platelet 13 × 10
9/ L, breast, ilium hypertrophy severe lower, and percentage of lymphocyte 90%, last diagnosis is " acute aplastic anemia ".Give antithymocyte globulin (ATG) commissural arch p0-357 A(CSA) treatment, be aided with infection, the process of blood product infusion.The state of an illness has no improvement.Take both Qi and blood deficiency of the present invention " aplastic anemia " enriching yin boost qi preparation pill, every day three times, each 10 balls.After taking 30 days, neutrophilic granulocyte > 1.0 × 10
9/ L, after this hemogram continues to rise.Treat hemogram after 4 months and recover normally (leukocyte 8.34 × 10 completely
9/ L, hemoglobin 125g/L, platelet 127 × 10
9/ L), without any clinical symptoms.Follow up a case by regular visits to so far, patient body in order, has recovered orthobiosis and study.
embodiment 5both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation, the primary raw material medicine getting following weight parts is prepared from (every part is 20g): Radix Codonopsis 14 parts, melilotus 8.5 parts, Herba Artemisiae Anomalae 3.8 parts, Caulis Spatholobi 13 parts, Caulis Bambusae In Taenia 16 parts, the Rhizoma Atractylodis Macrocephalae 15 parts, Herba Solidaginis 8 parts, Radix Stellariae Yunnanensis 7.5 parts, the pig iron falls 4.3 parts, Radix Platycodonis 9 parts, charred Petiolus Trachycarpi 4.5 parts.
The preparation method of above-mentioned both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation decoction is:
(1) enamel tray is put in electrothermostat reach after 180 DEG C, put into Petiolus Trachycarpi rapidly, toast 10 min, taking-up cools, and is ground into fine powder, crosses 170 mesh sieves, obtains charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is placed in marmite, adds water, amount of water is 4 times of the medicine gross weight added, and first boils to boiling with big fire, decocts with little fire afterwards, when to decoct to medicinal liquid be 1/3 of amount of water, leaches medicinal liquid;
(3) step (1) gained charred Petiolus Trachycarpi fine powder is joined in step (2) gained medicinal liquid, to obtain final product.
the diagnosis of aplastic anemia
Granulocytopenia and aplastic anemia international research group (1987) propose to diagnose aplastic anemia must meet at least 2 points in following 3: (1) hemoglobin < 100g/L; (2) platelet < 50 × 10
9/ L; (3) neutrophilic granulocyte < 1.5 × 10
9/ L.If though patient's peripheral blood two is or three be cytopenia, and reduces degree and do not reach above-mentioned standard, then should not be diagnosed as aplastic anemia, need monitoring cytometry change closely.
test example 1the clinical practice of embodiment 5 gained both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation decoction: in August, 2009 in December ,-2012, screen 272 routine aplastic anemia patients in 7 hospitals, wherein male 142 example, women 130 example, age 18-75 year, 35 years old mean age, course of disease 1-5, average course of disease 3 years.Be divided into two groups at random, experimental group and matched group (often organizing 136 examples), experimental group takes embodiment 5 products obtained therefrom, and using method is: take every day twice (warm), each 300mL.Matched group takes the medicine (as ciclosporin, androgen, antilymphocyte globulin/antithymocyte globulin (ALG/ATG), methyl meticortelone (MP), hematopoietic cell growth factor etc.) of other treatment aplastic anemia.Curative effect situation criterion: for the criterion of therapeutical effect of aplastic anemia, still adopts the standard that the 4th aplastic anemia academic conference in 1987 is formulated, and is divided into basic healing, alleviation, obviously progressive and invalid according to the recovery situation of patient.Basic healing: when not transfusing blood, anemia and bleeding disappear, and hemoglobin reaches male 120g/L, women 100g/L, and leukocyte reaches 4.0 × 10
9/ L, platelet reaches 80 × 10
9/ more than L, follows up a case by regular visits to and does not recur for more than 1 year; Alleviate: hemoglobin reaches male 120g/L, women 100g/L, follow up a case by regular visits to 3 months stable disease or continue progressive; Obvious progress: anemia and bleeding are clearly better, hemoglobin is comparatively treated first 1 month institute's measured value and is increased more than 30g/L, and can maintain more than 3 months.Invalid: through treatment, hemogram does not still have made marked progress.Total effectively comprising substantially cures and alleviates.Treat after four months, result is as shown in table 1.
Table 1: take embodiment 5 product 18-75 year aplastic anemia patient treatment outcome
As can be seen from Table 1, the experimental group total effective rate of embodiment 5 gained both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation decoction is used to reach 99.26%.And the total effective rate of matched group is only 69.85%.Experiment shows, experimental group and matched group have significant difference, and the successful of experimental group is better than matched group.
Radix Codonopsis, melilotus, Herba Artemisiae Anomalae and Caulis Spatholobi etc. suitably coordinate by the present invention, produce synergism after making these drug regimens, improve curative effect, safe and reliable, have good therapeutic effect to aplastic anemia.Radix Codonopsis invigorating the spleen and replenishing QI in side, spleen invigorating lung benefiting.Melilotus and middle stomach invigorating, clearing away heat and eliminating dampness, diuresis.Herba Artemisiae Anomalae has effect of anti-hypoxia, blood circulation promoting and blood stasis dispelling, removing food stagnancy, hemostasia and detumescence.Caulis Spatholobi is invigorated blood circulation, relaxing muscles and tendons.Caulis Bambusae In Taenia removing heat-phlegm, relieves restlessness and prevents vomiting, antiabortive removing heat from blood.Rhizoma Atractylodis Macrocephalae invigorating the spleen and benefiting QI, dampness diuretic, hidroschesis, antiabortive.Herba Solidaginis wind and heat dispersing, removing toxic substances and promoting subsidence of swelling.Radix Stellariae Yunnanensis strengthening spleen and nourishing blood, invigorating the liver and kidney, detumescence.The pig iron falls checking hyperfunction of the liver for relieving convulsion, and removing toxic substances sore, enriches blood.Radix Platycodonis has lung qi dispersing, sore-throat relieving, eliminates the phlegm, effect of evacuation of pus.Charred Petiolus Trachycarpi hemostasis with astringents.In formula, all medicine compatibilities, bring out the best in each other, and have the effects such as enriching yin boost qi, spleen invigorating lung benefiting, blood circulation promoting and blood stasis dispelling, hemostasia and detumescence, heat-clearing and toxic substances removing, invigorating the liver and kidney, blood-supplementing blood-nourishing, reach the object for the treatment of both the principal and secondary aspects of a disease, have no side effect.
Finally it should be noted that, embodiment is the detailed description of the invention of optimum of the present invention, be not limited to the present invention, although with reference to previous embodiment to invention has been detailed description, for a person skilled in the art, it still can be modified to the technical scheme described in foregoing embodiments, or carries out equivalent replacement to wherein portion of techniques feature.Within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (10)
1. both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation, is characterized in that, takes off the primary raw material medicine stating weight proportion and is prepared from: Radix Codonopsis 9-18, melilotus 6-12, Herba Artemisiae Anomalae 2-5, Caulis Spatholobi 10-15, Caulis Bambusae In Taenia 12-22, Rhizoma Atractylodis Macrocephalae 10-20, Herba Solidaginis 6-12, Radix Stellariae Yunnanensis 6-9, the pig iron falls 3-6, Radix Platycodonis 6-12, charred Petiolus Trachycarpi 3-6.
2. both Qi and blood deficiency according to claim 1 " aplastic anemia " enriching yin boost qi preparation, is characterized in that, takes off the primary raw material medicine stating weight proportion and is prepared from: Radix Codonopsis 12-16, melilotus 8-10, Herba Artemisiae Anomalae 3-4.3, Caulis Spatholobi 12-14, Caulis Bambusae In Taenia 15-18, Rhizoma Atractylodis Macrocephalae 13-17, Herba Solidaginis 7-9, Radix Stellariae Yunnanensis 7-8.5, the pig iron falls 4-5, Radix Platycodonis 8-11, charred Petiolus Trachycarpi 4-5.
3. both Qi and blood deficiency according to claim 1 " aplastic anemia " enriching yin boost qi preparation, is characterized in that, takes off the primary raw material medicine stating weight proportion and is prepared from: Radix Codonopsis 14, melilotus 8.5, Herba Artemisiae Anomalae 3.8, Caulis Spatholobi 13, Caulis Bambusae In Taenia 16, the Rhizoma Atractylodis Macrocephalae 15, Herba Solidaginis 8, Radix Stellariae Yunnanensis 7.5, the pig iron falls 4.3, Radix Platycodonis 9, charred Petiolus Trachycarpi 4.5.
4., according to arbitrary described both Qi and blood deficiency " aplastic anemia " the enriching yin boost qi preparation of claim 1-3, it is characterized in that, this both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation is made decoction, and the preparation method of described decoction is:
(1) after enamel tray is put in electrothermostat and reached 140-200 DEG C, put into Petiolus Trachycarpi rapidly, baking 5-15 min, taking-up cools, and is ground into fine powder, cross 150-190 mesh sieve (preferred, cross 160-180 mesh sieve; Be more preferably, cross 170 mesh sieves), obtain charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is placed in marmite, adds water, amount of water be the 3-5 of the medicine gross weight added doubly, first boil to boiling with big fire, to decoct with little fire afterwards, when to decoct to medicinal liquid be the 1/4-1/2 of amount of water, leach medicinal liquid;
(3) step (1) gained charred Petiolus Trachycarpi fine powder is joined in step (2) gained medicinal liquid, to obtain final product.
5. the preparation method of both Qi and blood deficiency according to claim 4 " aplastic anemia " enriching yin boost qi preparation decoction, it is characterized in that, in step (1) enamel tray put in electrothermostat reach 150-190 DEG C after (preferably enamel tray is put in electrothermostat and reaches after 180 DEG C).
6. the preparation method of both Qi and blood deficiency according to claim 4 " aplastic anemia " enriching yin boost qi preparation decoction, is characterized in that, in step (1), baking 8-12 min(preferably toasts 10 min).
7. the preparation method of both Qi and blood deficiency according to claim 4 " aplastic anemia " enriching yin boost qi preparation decoction, it is characterized in that, in step (2), amount of water is 3.5-4.5 times (preferred amount of water is 4 times of the medicine gross weight added) of the medicine gross weight added.
8. the preparation method of both Qi and blood deficiency according to claim 4 " aplastic anemia " enriching yin boost qi preparation decoction, is characterized in that, when to decoct to medicinal liquid in step (2) be the 2/7-2/5 of amount of water while being 1/3 of amount of water (preferably decoct to medicinal liquid).
9., according to arbitrary described both Qi and blood deficiency " aplastic anemia " the enriching yin boost qi preparation of claim 1-3, it is characterized in that, this both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation is made powder, and the preparation method of described powder is:
(1) enamel tray is put in electrothermostat and is reached 130-190 DEG C after (preferred, after enamel tray is put in electrothermostat and is reached 150-180 DEG C; Be more preferably, enamel tray put in electrothermostat and reaches after 165 DEG C), put into Petiolus Trachycarpi rapidly, baking 10-20 min(is preferred, baking 12-17min; Be more preferably, baking 15min), taking-up cools, and is ground into fine powder, crosses 130-170 mesh sieve and (preferably, crosses 140-160 mesh sieve; Be more preferably, cross 150 mesh sieves), obtain charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is removed impurity, pulverize respectively and grind to form fine powder, cross 130-170 mesh sieve and (preferably, cross 140-160 mesh sieve; Be more preferably, cross 150 mesh sieves);
(3) step (1) and step (2) gained fine powder are fully mixed, sterile packaged, often wrap 4 grams.
10., according to arbitrary described both Qi and blood deficiency " aplastic anemia " the enriching yin boost qi preparation of claim 1-3, it is characterized in that, this both Qi and blood deficiency " aplastic anemia " enriching yin boost qi preparation is made pill, and the preparation method of described pill is:
(1) enamel tray is put in electrothermostat and is reached 140-180 DEG C after (preferred, after enamel tray is put in electrothermostat and is reached 150-170 DEG C; Be more preferably, enamel tray put in electrothermostat and reaches after 160 DEG C), put into Petiolus Trachycarpi rapidly, baking 8-25 min(is preferred, baking 14-20min; Be more preferably, baking 17min), taking-up cools, and is ground into fine powder, crosses 140-180 mesh sieve and (preferably, crosses 150-170 mesh sieve; Be more preferably, cross 160 mesh sieves), obtain charred Petiolus Trachycarpi fine powder, for subsequent use;
(2) all the other except charred Petiolus Trachycarpi 10 taste Chinese crude drug is removed impurity, pulverize respectively and grind to form fine powder, cross 140-180 mesh sieve and (preferably, cross 150-170 mesh sieve; Be more preferably, cross 160 mesh sieves);
(3) step (1) and step (2) gained fine powder are fully mixed, add water, make little pill, the particle diameter of the little pill made is that 2-6mm(is preferred, and the particle diameter of the little pill made is 3-5mm; Be more preferably, the particle diameter of the little pill made is 4mm), dry and can obtain pill finished product of the present invention.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410738677.5A CN104491519A (en) | 2014-12-08 | 2014-12-08 | Yin-nourishing and qi-tonifying preparation for aplastic anemia due to dual depletion of qi and blood and preparation method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410738677.5A CN104491519A (en) | 2014-12-08 | 2014-12-08 | Yin-nourishing and qi-tonifying preparation for aplastic anemia due to dual depletion of qi and blood and preparation method |
Publications (1)
Publication Number | Publication Date |
---|---|
CN104491519A true CN104491519A (en) | 2015-04-08 |
Family
ID=52933033
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410738677.5A Pending CN104491519A (en) | 2014-12-08 | 2014-12-08 | Yin-nourishing and qi-tonifying preparation for aplastic anemia due to dual depletion of qi and blood and preparation method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104491519A (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1872236A (en) * | 2005-05-30 | 2006-12-06 | 白璋华 | Medication for treating aplastic anemia |
CN1911318A (en) * | 2006-08-15 | 2007-02-14 | 黄南锡 | Decoction of herbal medicine for treating insufficiency of both the spleen and the kidney type aplastic anemia, and its prepn. method |
CN101401891A (en) * | 2008-11-10 | 2009-04-08 | 郑磊 | Traditional Chinese medicine decoction for treating aplastic anemia |
KR20130036800A (en) * | 2011-10-05 | 2013-04-15 | 경희대학교 산학협력단 | A composition for stimulating immune response comprising an extract of angelicae gigantis radix and astragali radix |
CN103055123A (en) * | 2012-12-20 | 2013-04-24 | 合肥海大生物医药科技有限公司 | Traditional Chinese medicine composition for treating aplastic anemia and preparation method thereof |
CN103505607A (en) * | 2013-09-09 | 2014-01-15 | 吴承菊 | Traditional Chinese medicine composition used for treating aplastic anemia |
-
2014
- 2014-12-08 CN CN201410738677.5A patent/CN104491519A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1872236A (en) * | 2005-05-30 | 2006-12-06 | 白璋华 | Medication for treating aplastic anemia |
CN1911318A (en) * | 2006-08-15 | 2007-02-14 | 黄南锡 | Decoction of herbal medicine for treating insufficiency of both the spleen and the kidney type aplastic anemia, and its prepn. method |
CN101401891A (en) * | 2008-11-10 | 2009-04-08 | 郑磊 | Traditional Chinese medicine decoction for treating aplastic anemia |
KR20130036800A (en) * | 2011-10-05 | 2013-04-15 | 경희대학교 산학협력단 | A composition for stimulating immune response comprising an extract of angelicae gigantis radix and astragali radix |
CN103055123A (en) * | 2012-12-20 | 2013-04-24 | 合肥海大生物医药科技有限公司 | Traditional Chinese medicine composition for treating aplastic anemia and preparation method thereof |
CN103505607A (en) * | 2013-09-09 | 2014-01-15 | 吴承菊 | Traditional Chinese medicine composition used for treating aplastic anemia |
Non-Patent Citations (2)
Title |
---|
孟宪宗: "周信有教授治疗再生障碍性贫血用药经验", 《中医儿科杂志》 * |
马馨等: "《百医百顺》", 31 July 2006, 黑龙江人民出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102145064B (en) | Traditional Chinese medicine composition for treating senile vaginitis and preparation method thereof | |
CN103520572B (en) | A kind of Chinese medicine composition being used for the treatment of atopic dermatitis and preparation method thereof | |
CN103041256B (en) | Chinese herb preparation for curing recurrent respiratory tract infection of children | |
CN103041257B (en) | Chinese materia medica preparation for curing high fever and respiratory tract infection of children | |
CN102178781B (en) | Chinese medicine composition for treating scrotum eczema and preparation method thereof | |
CN103656048B (en) | Medicine being used for the treatment of mammitis of cow and preparation method thereof | |
CN103041255B (en) | Chinese materia medica preparation for curing swollen sore throat and respiratory tract infection of children | |
CN102973758A (en) | Traditional Chinese medicine composition for treating depression | |
CN104524479B (en) | A kind of Chinese medicine composition for treating premenstrual syndrome and preparation method thereof | |
CN104258224A (en) | Schisandra chinensis oral solution for treating lung-and-kidney yin-deficiency type chronic bronchitis and preparation method thereof | |
CN104206597B (en) | A kind of schisandra health care tea alleviating YIN-deficiency of the lung and kidney symptom and preparation method thereof | |
CN104306847A (en) | Six-ingredient qi-tonifying capsule and preparation process thereof | |
CN104491519A (en) | Yin-nourishing and qi-tonifying preparation for aplastic anemia due to dual depletion of qi and blood and preparation method | |
CN103330896B (en) | Preparation method of powder for treating postpartum nonspecific vaginitis | |
CN103041258B (en) | Chinese materia medica preparation for curing respiratory tract infection with poor appetite of children | |
CN101322788B (en) | Chinese medicine for treating vitiligo and preparation | |
CN101401881B (en) | Chinese medicinal composition for treating poison produced by venomous insects | |
CN104800573A (en) | Chinese medicinal composition for treating liver cancer and preparation method thereof | |
CN105833181A (en) | Traditional Chinese medicine composition for treating chronic pelvic inflammatory disease and preparing method thereof | |
CN105770760A (en) | Preparation for treating gastric ulcer and preparation method thereof | |
CN105582379A (en) | Traditional Chinese medicine composition for treating liver-stomach disharmony and preparation method of traditional Chinese medicine composition | |
CN105056160A (en) | Medicine composition for treating agalactia of cows and preparation method thereof | |
CN105168729A (en) | Traditional Chinese medicine composition for treating dampness-heat stagnation type dysmenorrhea | |
CN104958574A (en) | Traditional Chinese medicine preparation for treating cerebral concussion and preparation method of traditional Chinese medicine preparation | |
CN104888091A (en) | Traditional Chinese medicine composition for treating intestinal form of acute radiation sickness and preparation method of traditional Chinese medicine composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 246 No. 344000 Jiangxi province Fuzhou city Linchuan District Yuming Road Applicant after: Lv Fengrong Address before: Huaiyin District of Ji'nan City, Shandong province 250000 Ji Qi Road No. 112 Applicant before: Lv Fengrong |
|
COR | Change of bibliographic data | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150408 |